All In Biotech

Drug Trial Radar · NCT05396833

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

An Open-label, Multicenter Phase Ib Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the ATR Inhibitor Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors in Patients With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 320)

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

120

Actual

Start

Jun 7, 2022

Primary completion

Jul 14, 2026

Study completion Jul 14, 2026

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
May 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, clinical study conducted in multiple parts to establish the safety, tolerability, Pharmacokinetic/Pharmacodynamic (PK/PD) profile, maximum tolerated dose (MTD) combinations (if observed) and recommended dose for expansion (RDE) combination for tuvusertib in combination with lartesertib (in Part A1), food effect on the PK of lartesertib as monotherapy followed by treatment with tuvusertib in combination with lartesertib in participants with specific tumor types (in Part A1.1), relative bioavailability of a tuvusertib tablet formulation vs capsule formulation followed by treatment with tuvusertib (capsule) in combination with lartesertib in participants with specific tumor types (in Part A1.2), safety/tolerability and early signs of clinical activity of tuvusertib (capsule)and lartesertib in combination in participants with prostate cancer harboring loss of function (LoS) mutation in the gene ATM based on historic data collected prior to prescreening in circulating tumor (ct) DNA (liquid biopsies) or tumor biopsies (in Part A2), safety/tolerability and early signs of clinical activity of tuvusertib and lartesertib in combination in participants with endometrial cancer harboring LoS mutation(s) in the gene ARID1A based on historic data collected prior to prescreening in ctDNA (liquid biopsies) or tumor biopsies (in Part A3), the relative bioavailability of a tuvusertib tablet formulation (TF1, test) compared to a capsule formulation (reference) will also be investigated (in Part A2/A3), and identify a potential set of MTD combinations, and establish the RDE for the combination of tuvusertib and avelumab in participants with metastatic or locally advanced unresectable solid tumors (in Part B1).

Conditions

  • Metastatic or Locally Advanced Unresectable Solid Tumors

Interventions

  • TuvusertibDrug

    Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.

  • LartesertibDrug

    Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.

  • AvelumabDrug

    Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A1: Number of Participants With Dose-Limiting Toxicities (DLTs) During the DLT Evaluation PeriodTime frame: Day 1 up to Day 28
  2. Part A1: Number of Participants With Adverse Events (AEs) and Treatment-Related AEsTime frame: Baseline up to 18 months
  3. Part B1: Number of Participants with Dose-Limiting Toxicities (DLTs) During the DLT Evaluation PeriodTime frame: Day 1 up to Day 28
  4. Part B1: Number of Participants with AEs and Treatment-Related AEsTime frame: Baseline up to 18 months
  5. Part A1: Change From Baseline in Pharmacodynamic (PD) BiomarkerTime frame: Pre-dose up to approximately 1 month
  6. Part B1: Change From Baseline in PD BiomarkerTime frame: Pre-dose up to approximately 1 month
  7. Part A1.1: PK Plasma Concentration of Lartesertib Under Fed and Fasted ConditionsTime frame: Day -1 up to Period 1 Day 1
  8. Part A2/A3: Objective Response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by InvestigatorTime frame: Up to 18 months after first dose administration
  9. Part A2/A3: Number of Participants With AEs and Treatment-Related AEsTime frame: Baseline up to 18 months
  10. Part A1.2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentTime frame: Day -4 up to Period 1 Day 1
  11. Part A1.2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero to Last Quantifiable Concentration [Frel(AUC0-t)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentTime frame: Day -4 up to Period 1 Day 1
  12. Part A1.2: Ratio Maximum Observed Plasma Concentration (Ratio[Cmax]) of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentTime frame: Day -4 up to Period 1 Day 1
  13. Part A2/A3: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentTime frame: Day -4 up to Period 1 Day 1
  14. Part A2/A3: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero to Last Quantifiable Concentration [Frel(AUC0-t)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentTime frame: Day -4 up to Period 1 Day 1
  15. Part A2/A3: Ratio Maximum Observed Plasma Concentration (Ratio[Cmax]) of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentTime frame: Day -4 up to Period 1 Day 1

Locations

22 sites in 5 countries. Site status is shown where the registry gives one.

  • Providence Medical Foundation

    Santa Rosa, California

  • University of Miami School of Medicine

    Miami, Florida

  • Augusta University - formerly Georgia Regents University

    Augusta, Georgia

  • The University of Kansas Medical Center Research Institute, Inc.

    Kansas City, Kansas

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Mary Crowley Cancer Research Centers

    Dallas, Texas

  • University of Texas M. D. Anderson Cancer Center - Partner

    Houston, Texas

  • NEXT Oncology

    San Antonio, Texas

  • Royal North Shore Hospital

    St Leonards, Australia

  • Calvary Mater Newcastle - PARENT

    Waratah, Australia

  • Princess Margaret Cancer Centre

    Toronto, Canada

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Severance Hospital, Yonsei University Health System - Division of Infectious Diseases

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Hospital QuironSalud Barcelona - Next Oncology

    Barcelona, Spain

  • Hospital Clinic de Barcelona - Servicio de Oncologia

    Barcelona, Spain

  • Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica

    Madrid, Spain

  • Hospital Universitario Quironsalud Madrid - NEXT Oncology

    Madrid, Spain

  • Hospital Universitario Fundacion Jimenez Diaz - START Madrid FJD - Oncology Phase I

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.